Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
This trial is active, not recruiting.
|Conditions||inflammatory bowel disease (ibd), primary sclerosing cholangitis (psc), colorectal neoplasms, colorectal cancer|
|Sponsor||Exact Sciences Corporation|
|Start date||March 2013|
|End date||December 2016|
|Trial size||440 participants|
|Trial identifier||NCT01819766, Exact Sciences 2013-01|
This study aims to determine the performance of the Exact IBD-ACRN surveillance test to detect colorectal cancer (CRC) and colorectal neoplasia in patients with inflammatory bowel disease (IBD). Patients with an IBD diagnosis for at least eight years or diagnosis of primary sclerosing cholangitis (PSC) and who are eligible for CRC screening are eligible to participate in this study. Enrolled subjects will collect a stool sample for the Exact IBD-ACRN surveillance test. Subjects must have undergone colonoscopy no more than 90 days prior to enrollment and will undergo colonoscopy or surgical intervention within 120 days of enrollment. Tissue diagnosis of CRC will be established by histopathologic examination.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Phoenix, AZ||Mayo Clinic Arizona||no longer recruiting|
|La Jolla, CA||UC San Diego Medical Center||no longer recruiting|
|Miami, FL||University of Miami||no longer recruiting|
|Chicago, IL||Rush University Medical Center||no longer recruiting|
|Chicago, IL||University of Chicago Medicine||no longer recruiting|
|Evanston, IL||NorthShore University Health System||no longer recruiting|
|Baton Rouge, LA||Gastroenterology Associates, LLC||no longer recruiting|
|Chevy Chase, MD||MGG Group, Co. Inc./Chevy Chase Clinical Research||no longer recruiting|
|Boston, MA||Massachusetts General Hospital||no longer recruiting|
|Boston, MA||Boston Medical Center||no longer recruiting|
|Farmington Hills, MI||Detroit Clinical Research Center, PC||no longer recruiting|
|Rochester, MN||Mayo Clinic||no longer recruiting|
|Mexico, MO||Center for Digestive and Liver Diseases, Inc||no longer recruiting|
|New York, NY||Mount Sinai School of Medicine||no longer recruiting|
|New York, NY||Medical Research Associates of New York||no longer recruiting|
|Asheville, NC||Asheville Gastroeneterology Associates||no longer recruiting|
|Chapel Hill, NC||Univeristy of North Carolina||no longer recruiting|
|Cleveland, OH||Cleveland Clinic||no longer recruiting|
|Nashville, TN||Vanderbilt University Medical Center||no longer recruiting|
|Houston, TX||Houston Methodist Hospital||no longer recruiting|
|Logan, UT||Advanced Research Institute||no longer recruiting|
|Lynchburg, VA||Blue Ridge Medical Research||no longer recruiting|
|Madison, WI||University of Wisconsin Hospital and Clinics||no longer recruiting|
|Milwaukee, WI||Wisconsin Center for Advanced Research||no longer recruiting|
|Calgary, Canada||University of Calgary||no longer recruiting|
|Winnipeg, Canada||Winnipeg Regional Health Authority-Health Sciences||no longer recruiting|
|Observational model||case control|
Subjects will be men and women, 18 to 84 years of age, inclusive, who are at increased risk of developing colorectal cancer.
Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC.
time frame: 9 months
Determine Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC and HGD.
time frame: 9 months
Male or female participants from 18 years up to 84 years old.
Inclusion Criteria: - Male or female 18-84 years of age, inclusive. - Diagnosis of IBD or a diagnosis of PSC with IBD prior to enrollment date of this study. - Must be a candidate for a surveillance colonoscopy, with the intention of CRC/dysplasia surveillance, or a candidate for surgical intervention based on prior histological confirmation of HGD or CRC. - Written informed consent document signed and dated by the subject or legally acceptable representative. Exclusion Criteria: - Any condition that in the opinion of the investigator should preclude participation in the study. - A history of aerodigestive tract cancer. - Prior colorectal resection, except ileocolic resection in Crohn's disease patients. - IBD limited only to the rectum and without a concurrent PSC diagnosis. - Subject has participated in any clinical study within the previous 30 days wherein an investigational compound or device was, or may be, introduced into the subject.
|Official title||Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study|
|Principal investigator||Steven Itzkowitz, MD|
|Description||This is a prospective, cross sectional, multi-center study to determine the sensitivity and specificity of the Exact IBD-ACRN surveillance test for detecting CRC alone and in combination with high grade dysplasia (HGD) and low grade dysplasia (LGD) associated with IBD and advanced adenoma in IBD patients with disease duration greater than 8 years or PSC diagnosis. Enrolled subjects will provide a single stool sample for the Exact IBD-ACRN surveillance test, no sooner than 7 days following their most recent pre-enrollment colonoscopy, within 30 days of enrollment and prior to initiating bowel prep for either the post-enrollment colonoscopy (surveillance or repeat), or surgical intervention. Stool samples will be tested using the Exact IBD-ACRN surveillance test and results compared to the colonoscopy and corresponding diagnostic histopathology results from biopsied, and any subsequently excised, lesions to establish sensitivity and specificity of the Exact IBD-ACRN surveillance test. All post-enrollment colonoscopies or surgical interventions must be performed within 60 days of enrollment. The primary objective of this study is to determine the sensitivity and specificity of the Exact IBD-ACRN surveillance test for CRC in IBD patients with disease duration of at least eight years or diagnosis of PSC. Tissue diagnosis of CRC will be established by histopathology examination. The secondary objective is to determine the sensitivity and specificity of the Exact IBD-ACRN surveillance test to detect ACRN in IBD patients with disease duration of at least eight years or diagnosis of PSC. Enrollment will continue until at least 35 CRC; 15 HGD and 315 negative subject samples have been obtained. There is no specific recruitment goal for IBD associated LGD or LGD associated with advanced adenoma (AA).|
Call for more information